Repurposing Drugs in Oncology (ReDO) - Itraconazole as an anti-cancer agent

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Pantziarka, Pan ^a,b   Sukhatme, Vidula ^c   Bouche, Gauthier ^a   Meheus, Lydie ^a   Sukhatme, Vikas P ^c,d  

^a Anticancer Fund   (Belgium)

^b George Pantziarka TP53 Trust   (United Kingdom)

^c GlobalCures Inc   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Drug repurposing; Hedgehog pathway inhibition; Itraconazole; ReDO project

Indexed keywords

ITRACONAZOLE; SONIC HEDGEHOG PROTEIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BASAL CELL CARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG REPOSITIONING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; LUNG CANCER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; SIGNAL TRANSDUCTION;

EID: 84934940315     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.521     Document Type: Article

References (47)

1. Lestner J and Hope WW (2013) Itraconazole: an update on pharmacology and clinical use for treatment of invasive and allergic fungal infections Expert opinion on drug metabolism & toxicology 9(7) pp 911-26
2. Joint-Formulary-Committee (2015) British National Formulary 69th ed., BMJ Group and Pharmaceutical Press
3. Gupta AK, Cooper EA and Ginter G (2003) Efficacy and safety of itraconazole use in children Dermatologic Clinics 21(3) pp 521-535
4. Barone JA et al (1993) Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers Pharmacotherapy 18(4) pp 295-301
5. Barone JA et al (1998) Enhanced bioavailability of itraconazole in hydroxypropyl-beta- cyclodextrin solution versus capsules in healthy volunteers Antimicrob Agents Chemother 42(7) pp 1862-5 PMID: 9661037 PMCID: 105699
6. Poirier JM and Cheymol G (1998) Optimisation of itraconazole therapy using target drug concentrations Clin Pharmacokinet 35(6) pp 461-73 DOI: 10.2165/00003088-199835060-00004
7. Felton T, Troke PF and Hope WW (2014) Tissue penetration of antifungal agents Clin Microbiol Rev 27(1) pp 68-88 DOI: 10.1128/CMR.00046-13 PMID: 24396137 PMCID: 3910906
8. Odds FC and Bossche HV (2000) Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro J Antimicrob Chemother 45(3) pp 371-3 DOI: 10.1093/jac/45.3.371 PMID: 10702560
9. Mc Evoy GK and Snow EK (2008) AHFS: Drug Information Bethesda MD American Society of Health-System Pharmacists
10. Bermúdez M et al (2005) Itraconazole-related increased vincristine neurotoxicity: case report and review of literature J Pediatr Hematol Oncol 27(7) 389-92 DOI: 10.1097/01.mph.0000172751.06286.5b PMID: 16012330
11. Takahashi N et al (2008) Itraconazole oral solution enhanced vincristine neurotoxicity in five patients with malignant lymphoma Intern Med 47(7) 651-3 DOI: 10.2169/internalmedicine.47.0701 PMID: 18379154
12. Summers KK et al (1997) Therapeutic drug monitoring of systemic antifungal therapy J Antimicrob Chemother 40(6) pp 753-64 DOI: 10.1093/jac/40.6.753
13. Kim JS et al (2014) The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a Ann Hematol 93(1) pp 33-42 DOI: 10.1007/s00277-013-1826-x
14. Gupta S, Kim J and Gollapudi S (1991) Reversal of daunorubicin resistance in P388/ADR cells by itraconazole J Clin Invest 87(4) pp 1467-9 DOI: 10.1172/JCI115154 PMID: 1849151 PMCID: 295200
15. Kurosawa M et al (1996) Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells Ann Hematol 72(1) pp 17-21 DOI: 10.1007/BF00663011 PMID: 8605275
16. Gupta A, Unadkat JD and Mao Q (2007) Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP) J Pharm Sci 96(12) pp 3226-35 DOI: 10.1002/jps.20963 PMID: 17518356
17. Chong CR et al (2007) Inhibition of angiogenesis by the antifungal drug itraconazole ACS Chem Biol 2(4) pp 263-70 DOI: 10.1021/cb600362d PMID: 17432820
18. Nacev BA and Liu JO (2011) Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole PloS One 6(9) p e24793 DOI: 10.1371/journal.pone.0024793 PMID: 21969860 PMCID: 3182171
19. Aftab BT et al (2011) Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer Cancer Res 71(21) pp 6764-72 DOI: 10.1158/0008-5472.CAN-11-0691 PMID: 21896639 PMCID: 3206167
20. Kim J et al (2010) Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth Cancer Cell 17(4) pp 388-99 DOI: 10.1016/j.ccr.2010.02.027 PMID: 20385363 PMCID: 4039177
21. Sánchez C et al (1995) Treatment of cerebral Aspergillosis with itraconazole: do high doses improve the prognosis? Clin Infect Dis 21(6) pp 1485-7 DOI: 10.1093/clinids/21.6.1485 PMID: 8749640
22. Kim J et al (2013) Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists Cancer Cell 23(1) pp 23-34 DOI: 10.1016/j.ccr.2012.11.017 PMID: 23291299 PMCID: 3548977
23. You M et al (2014) Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro J Thorac Cardiovasc Surg 147(1) pp 508-16 DOI: 10.1016/j.jtcvs.2013.08.035
24. Liu R et al (2014) Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking Autophagy 10(7) pp 1241-55 DOI: 10.4161/auto.28912 PMID: 24905460 PMCID: 4203550
25. Ringshausen I et al (2010) Antifungal therapy with itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts Cancer Res 70(11) pp 4292-6 DOI: 10.1158/0008-5472.CAN-10-0259 PMID: 20460536
26. Vreugdenhil G et al (1993) Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia Ann Hematol 67(3) pp 107-9 DOI: 10.1007/BF01701730 PMID: 8396989
27. Antonarakis ES et al (2013) Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer Oncologist 18(2) pp 163-73 DOI: 10.1634/theoncologist.2012-314 PMID: 23340005 PMCID: 3579600
28. Suzman DL and Antonarakis ES (2014) High-dose itraconazole as a noncastrating therapy for a patient with biochemically recurrent prostate cancer Clin Genitourin Cancer 12(2) pp e51-3 DOI: 10.1016/j.clgc.2013.11.015
29. Rudin CM et al (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer J Thorac Oncol 8(5) pp 619-23 PMID: 23546045 PMCID: 3636564
30. Kim DJ et al (2014) Open-Label, Exploratory Phase II Trial of Oral Itraconazole for the Treatment of Basal Cell Carcinoma J Clinic Oncol 32(8) pp 745-51 DOI: 10.1200/JCO.2013.49.9525
31. Tsubamoto H et al (2014) Impact of combination chemotherapy with itraconazole on survival for patients with recurrent or persistent ovarian clear cell carcinoma Anticancer Res 34(4) pp 2007-14 PMID: 24692739
32. Tsubamoto H et al (2014) Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer Anticancer Res 34(5) pp 2481-7 PMID: 24778064
33. Tsubamoto H, Sonoda T and Inoue K (2014) Impact of Itraconazole on the Survival of Heavily Pre-treated Patients with Triple-Negative Breast Cancer Anticancer Res 34(7) pp 3839-44 PMID: 24982411
34. Ademuyiwa FO et al (2011) A pilot trial of itraconazole pharmacokinetics in patients with metastatic breast cancer J Clin Oncol suppl pp abstr e13565
35. Lockhart NR, Waddell JA and Schrock NE (2015) Itraconazole therapy in a pancreatic adenocarcinoma patient: A case report J Oncol Pharm Pract DOI: 10.1177/1078155215572931 PMID: 25670260
36. Cooper SM, Sheridan A and Burge S (2003) Mycosis fungoides responding to systemic itraconazole Journal of the European Academy of Dermatology and Venereology 17 pp 588-590
37. Kast RE, Karpel-Massler G and Halatsch M (2014) CUSP9∗treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide Oncotarget 5(18) pp 8052-82 PMID: 25211298 PMCID: 4226667
38. Xu J et al (2010) Cholesterol trafficking is required for mTOR activation in endothelial cells Proc Nat Acad Sci USA 107(10) pp 4764-9 DOI: 10.1073/pnas.0910872107 PMID: 20176935 PMCID: 2842052
39. Nacev BA et al (2011) The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells J Biol Chem 286(51) pp 44045-56 DOI: 10.1074/jbc.M111.278754 PMID: 22025615 PMCID: 3243534
40. Ran Y et al (2015) Successful treatment of oral itraconazole for infantile hemangiomas: A case series J Dermatol (February) 42(2) pp 202-6 DOI: 10.1111/1346-8138.12724
41. Yu Z et al (2012) Cancer stem cells Int J Biochem Cell Biol 44(12) pp 2144-2151 DOI: 10.1016/j.biocel.2012.08.022 PMID: 22981632 PMCID: 3496019
42. Yang Y et al (2013) RARα2 expression confers myeloma stem cell features Blood 122(8) pp 1437-47 DOI: 10.1182/blood-2013-02-482919 PMID: 23847194 PMCID: 3750340
43. Callaghan R, Luk F and Bebawy M (2014) Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 42(4) pp 623-31 DOI: 10.1124/dmd.113.056176 PMID: 24492893 PMCID: 3965902
44. Wang E et al (2002) Interaction of common azole antifungals with P glycoprotein Antimicrob Agents Chemother 46(1) pp 160-5 DOI: 10.1128/AAC.46.1.160-165.2002
45. Noguchi K, Katayama K and Sugimoto Y (2014) Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics Pharmacogenomics Pers Med 7 pp 53-64 DOI: 10.2147/PGPM.S38295
46. Pricl S et al (2014) Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma Mol Oncol 9(2) 389-97 DOI: 10.1016/j.molonc.2014.09.003 PMID: 25306392
47. Otsuka A et al (2015) Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma Clin Cancer Res 21(6) 1289-97 DOI: 10.1158/1078-0432.CCR-14-2110 PMID: 25593302